Introduction Little data is available on patients with advanced non-squamous NSCLC
treated with erlotinib specifically after failure of first-line pemetrexed-containing …

Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

ABSTRACT Background Erlotinib (E) and Pemetrexed (P) are approved second-line
treatments in patients (pts) with relapsed NSCLC and may be effective in combination. This …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …

Background Erlotinib and pemetrexed have been approved for the second-line treatment of
non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

Introduction Erlotinib and pemetrexed have been approved for the second-line and
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …

Abstract Background/Aim: Erlotinib and chemotherapy have shown similar efficacy for
pretreated non-small cell lung cancer (NSCLC) patients, but none of the large studies have …